Bristol Myers Squibb Says EC Approves Inrebic to Treat Myelofibrosis Patients

By Stephen Nakrosis

Bristol Myers Squibb Co. on Monday said the European Commission gave full marketing authorization for Inrebic to treat some myelofibrosis patients.

The company said Inrebic, or fedratinib, received the authorization for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis, who are Janus Associated Kinase inhibitor naive or have been treated with ruxolitinib.

The authorization covers all European Union member states, as well as Norway, Iceland and Liechtenstein, but doesn't include approval in Great Britain, the company said.

Myelofibrosis is a rare bone marrow cancer that disrupts the body's production of red blood cells.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

February 08, 2021 13:11 ET (18:11 GMT)

Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024